MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Proteon Therapeutics Company Profile (NASDAQ:PRTO)

Consensus Ratings for Proteon Therapeutics (NASDAQ:PRTO) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.50 (258.33% upside)

Analysts' Ratings History for Proteon Therapeutics (NASDAQ:PRTO)
Show:
DateFirmActionRatingPrice TargetActions
4/13/2016Robert W. BairdInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Stifel NicolausLower Price TargetBuy$20.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$22.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Raymond JamesInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2014OppenheimerInitiated CoverageOutperform$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Proteon Therapeutics (NASDAQ:PRTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/9/2016Q1($0.41)($0.40)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016($0.34)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.33)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.30)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015($0.24)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/20/2015($0.26)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/26/2014($0.31)($31.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Proteon Therapeutics (NASDAQ:PRTO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.42)($0.42)($0.42)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)
Dividend History for Proteon Therapeutics (NASDAQ:PRTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Proteon Therapeutics (NASDAQ:PRTO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016George Arthur EldridgeCFOBuy4,000$5.78$23,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Timothy P. NoyesCEOSell5,000$14.97$74,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Timothy P. NoyesCEOSell5,000$13.50$67,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Timothy P. NoyesCEOSell5,000$13.33$66,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Timothy P. NoyesCEOSell5,000$13.55$67,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015Daniel Philip GottliebVPSell1,965$16.86$33,129.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014James E FlynnInsiderBuy691,713$10.00$6,917,130.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Skyline Venture Partners QualiMajor ShareholderSell56,038$10.00$560,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Timothy HainesDirectorBuy950,000$10.00$9,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Proteon Therapeutics (NASDAQ:PRTO)
DateHeadline
06/24/16 07:45 AMProteon Therapeutics (PRTO) in Focus: Stock Gains 6.4% -
06/15/16 07:29 AMProteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd - [at noodls] - WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and ...
06/13/16 07:01 AMPROTEON THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/08/16 05:07 PMProteon Therapeutics, Inc. :PRTO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
05/09/16 07:28 AMProteon Therapeutics reports 1Q loss -
05/09/16 07:18 AMProteon Therapeutics Announces First Quarter 2016 Financial Results - [at noodls] - WALTHAM, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and ...
05/09/16 07:02 AMPROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
04/28/16 06:22 AMProteon Therapeutics Announces Survey Findings Demonstrating Impact of Vascular Access Failure on Hemodialysis Patients - [at noodls] - WALTHAM, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney ...
04/14/16 04:41 AMCoverage initiated on Proteon Therapeutics by Robert W. Baird -
04/13/16 08:33 AMProteon Therapeutics Reports Publication of Promising Nonclinical Results from Vonapanitase in Peripheral Artery Disease - Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD). The ex vivo study demonstrated that a single treatment of vonapanitase following angioplasty of excised atherosclerotic human tibial arteries altered artery compliance. Increased compliance is known to correlate with arterial dilation. The study, titled "Recombinant Human Elastase Alters the Compliance of Atherosclerotic Tibial Arteries After Ex Vivo Angioplasty", was published in the Journal of Cardiovascular Pharmacology. Proteon's Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. PAD is often caused by atherosclerosis and can frequently occur in the tibial arteries, which are located below the knee ...Full story available on Benzinga.com
04/13/16 07:24 AMProteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease - [at noodls] - WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney ...
03/14/16 07:57 AMProteon Therapeutics reports 4Q loss -
03/14/16 07:30 AMProteon Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results - [GlobeNewswire] - WALTHAM, Mass., March 14, 2016-- Proteon Therapeutics Inc., a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today ...
02/02/16 07:00 AMProteon Therapeutics to Present at the 2016 BIO CEO & Investor Conference February 8th - [GlobeNewswire] - WALTHAM, Mass., Feb. 02, 2016-- Proteon Therapeutics Inc., a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced ...
01/22/16 07:31 AMPROTEON THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement -
12/08/15 12:17 PMPROTEON THERAPEUTICS INC Financials -
12/02/15 07:00 AMProteon Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference December 9th - [GlobeNewswire] - WALTHAM, Mass. -- Proteon Therapeutics Inc. , a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that ...
11/13/15 06:45 AMProteon Therapeutics to Present at the Stifel 2015 Healthcare Conference on November 17th - [GlobeNewswire] - WALTHAM, Mass. -- Proteon Therapeutics Inc. , a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that ...
11/12/15 03:17 PMPROTEON THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh -
11/12/15 08:25 AMProteon Therapeutics reports 3Q loss -
11/12/15 07:26 AMProteon Therapeutics Announces Third Quarter 2015 Financial Results - [at noodls] - Proteon Therapeutics Announces Third Quarter 2015 Financial Results
11/09/15 10:58 AMProteon Therapeutics to Host Research and Development Day on November 20, 2015 - [GlobeNewswire] - WALTHAM, Mass. -- Proteon Therapeutics Inc. , a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it ...
11/02/15 03:17 PMPROTEON THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
11/02/15 03:15 PMProteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational Vonapanitase - [GlobeNewswire] - WALTHAM, Mass. -- Proteon Therapeutics Inc. , a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it ...
10/28/15 04:00 PMProteon Therapeutics to Present at the BIO-Europe 2015 Conference November 3 - [GlobeNewswire] - WALTHAM, Mass. -- Proteon Therapeutics Inc. , a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company ...
10/19/15 07:31 AMProteon Therapeutics Appoints Tony Kingsley to Its Board of Directors - [at noodls] - Proteon Therapeutics Appoints Tony Kingsley to Its Board of Directors
10/19/15 07:02 AMPROTEON THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi -
10/12/15 07:25 AMProteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 - [at noodls] - Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015
About Proteon Therapeutics

Proteon Therapeutics logoProteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PRTO
  • CUSIP:
Key Metrics:
  • Previous Close: $6.00
  • 50 Day Moving Average: $6.35
  • 200 Day Moving Average: $8.60
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $99.40M
  • Current Quarter EPS Consensus Estimate: $-1.77 EPS
Additional Links:
Proteon Therapeutics (NASDAQ:PRTO) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha